Poplar Therapeutics
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
$45MSeries A+
Role not disclosedAP
ArrowMark Partners
Activity from announced rounds
Activity in this selectionnomura-real-estate-development-co-f095adde
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $345M 2 disclosed · full round size, not this investor’s share